22qDS: 22q11.2 deletion syndrome; CDR: complementarity-determining region; DGS: DiGeorge syndrome; IgE: immunoglobulin E; IgM: immunoglobulin M; SCID: severe combined immunodeficiency; TREC: T cell receptor excision circle.
* Use of the term 22qDS is preferred for patients with this genetic defect and a DGS phenotype, with the term DGS reserved for patients who have phenotypic features consistent with DGS but do not have a 22q11.2 deletion (they may have a different pathogenic variant associated with the syndrome or no identified genetic defect).
¶ More extensive testing prior to definitive therapy is recommended because the rare presence of other inborn errors of immunity may impact choice of therapy (thymic transplant versus hematopoietic cell transplantation). Patients also rarely have coexisting conditions due to other genetic defects.
Δ Refer to UpToDate topics on 22q11.2 deletion/DiGeorge syndrome for details on diagnosis and differential diagnosis.
◊ B cell function can be assessed by measuring IgM levels. Refer to UpToDate topics on humoral immunodeficiency and laboratory evaluation of the immune system for additional details.